Avacopan with combined cyclophosphamide and rituximab for induction therapy in severe ANCA-associated vasculitis: retrospective observational study of 30 patients in two German referral centres
In this observational study, avacopan as GC-sparing agent appeared safe and efficacious in combination with RTX and CYC for remission induction in severe ANCA-associated vasculitis. In this subgroup, prospective studies are needed to determine the efficacy and safety of avacopan in combination with RTX and CYC for guidance of a GC-sparing strategy.
Authors
- Peter Lamprecht (ORCID: https://orcid.org/0000-0001-5929-868X)
- G. Aßmann (ORCID: https://orcid.org/0000-0002-3216-9340)
- Kerstin Amann (ORCID: https://orcid.org/0000-0001-6116-8315)
- El‐Baraa Adjailia
- Sebastian Klapa (ORCID: https://orcid.org/0000-0002-0012-0163)
- R Turkiewicz
- J. Radermacher
- Katja von Allwoerden
Institutions
- Universitätsklinikum Erlangen (DE)
- Johannes Wesling Klinikum Minden (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Clinical and Experimental Rheumatology
- Published
- 2024-12-05
- DOI
- https://doi.org/10.55563/clinexprheumatol/7sz0zp
- Citations
- 1
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.42
Funders
- Pfizer
- AstraZeneca
- Bundesministerium für Bildung und Forschung
- Bundesministerium der Verteidigung
- Vifor Pharma